Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,605 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association between the Worst Pattern of Tumor Invasion and Epithelial-mesenchymal Transition and their Prognostic Impact on Early-stage Oral Tongue Squamous Cell Carcinoma.
Divya GM, Thomas S, Anila KR, Kannan S, Vimal J, Varghese BT, Iype EM, George NA, Mathew A. Divya GM, et al. Among authors: mathew a. Indian J Otolaryngol Head Neck Surg. 2024 Oct;76(5):4307-4315. doi: 10.1007/s12070-024-04842-1. Epub 2024 Jul 8. Indian J Otolaryngol Head Neck Surg. 2024. PMID: 39376349
Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma.
Sharon CE, Tortorello GN, Ma KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Miura JT, Karakousis GC, Mitchell TC. Sharon CE, et al. Among authors: mathew aj. Ann Oncol. 2023 Sep;34(9):806-812. doi: 10.1016/j.annonc.2023.06.006. Epub 2023 Jul 4. Ann Oncol. 2023. PMID: 37414215 Free PMC article. Clinical Trial.
Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812].
Sharon CE, Tortorello GN, Ma KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Miura JT, Karakousis GC, Mitchell TC. Sharon CE, et al. Among authors: mathew aj. Ann Oncol. 2024 Aug;35(8):756. doi: 10.1016/j.annonc.2024.03.002. Epub 2024 Apr 13. Ann Oncol. 2024. PMID: 38614876 Free PMC article. No abstract available.
Determinants of physical function, as measured using PROMIS PF-10a, in patients with rheumatoid arthritis: results from the international COVID-19 Vaccination in Autoimmune Diseases (COVAD) study.
Ali SS, Demetriou C, Parodis I, Tan AL, Edgar Gracia-Ramos A, Joshi M, Caballero-Uribe CV, Saha S, Lilleker JB, Nune A, Pauling JD, Wincup C, Jagtap K, Dey D, Milchert M, Distler O, Chinoy H, Agarwal V, Gupta L, Nikiphorou E; COVAD Study Group. Ali SS, et al. Rheumatol Adv Pract. 2024 Dec 30;9(1):rkae154. doi: 10.1093/rap/rkae154. eCollection 2025. Rheumatol Adv Pract. 2024. PMID: 39846050 Free PMC article.
CAR T access and outcomes in large B-cell lymphoma according to ethnicity and socioeconomic deprivation in the UK.
Dragoi D, Cusworth S, Oldham L, Sanderson R, Norman J, Chandan J, Mathew A, Kumar E, Paneesha S, Tholouli E, Moya Davila A, Bouziana S, Patten P, Hardefeldt P, Yallop D, Chaganti S, Burns D, Kuhnl A. Dragoi D, et al. Among authors: mathew a. Br J Haematol. 2025 Jan 16. doi: 10.1111/bjh.19997. Online ahead of print. Br J Haematol. 2025. PMID: 39821591
Access to timely cancer treatment initiation in India: extent, determinants and trends.
Halder P, Dixit J, Gupta N, Mehra N, Singh A, Malhotra P, Mathew A, Kumar L, Chandra Kataki A, Gupta S, Prinja S. Halder P, et al. Among authors: mathew a. Lancet Reg Health Southeast Asia. 2024 Dec 18;32:100514. doi: 10.1016/j.lansea.2024.100514. eCollection 2025 Jan. Lancet Reg Health Southeast Asia. 2024. PMID: 39802701 Free PMC article.
1,605 results